Identification and Verification of SLC27A1, PTBP1 and EIF5A With Significantly Altered Expression in Aggressive Pituitary Adenomas
BackgroundAggressive pituitary adenoma encircling the internal carotid artery has a poor clinical prognosis because of a high surgical risk and a high recurrence rate. This seriously affects patients’ quality of life and yet there is no effective medical treatment. The European Diagnostic Guidelines...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Surgery |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fsurg.2022.923143/full |
| _version_ | 1818545561317408768 |
|---|---|
| author | Jianhua Cheng Ruya Sun Ding Nie Bin Li Song Bai Gui Chu Zhong Li Ya Zhuo Zhang Peng Zhao |
| author_facet | Jianhua Cheng Ruya Sun Ding Nie Bin Li Song Bai Gui Chu Zhong Li Ya Zhuo Zhang Peng Zhao |
| author_sort | Jianhua Cheng |
| collection | DOAJ |
| description | BackgroundAggressive pituitary adenoma encircling the internal carotid artery has a poor clinical prognosis because of a high surgical risk and a high recurrence rate. This seriously affects patients’ quality of life and yet there is no effective medical treatment. The European Diagnostic Guidelines have recommended the use of temozolomide (TMZ) for these aggressive pituitary adenomas, but the treatment remission rate has been less than 50%.MethodsIn this study, transcriptome sequencing of pituitary tumour tissues and TMZ-treated pituitary tumour cell lines were employed to explore the significance gene expressions affecting the efficacy of TMZ treatment for pituitary tumours. To clarify the roles of these gene expressions, six adult patients with pituitary adenomas treated in Tiantan Hospital from 2015 to 2020 and a pituitary adenoma cell line (Att20 sensitive to TMZ treatment) were analyzed by mRNA transcriptome sequencing. The differentially expressed genes were assayed by analyzing the sequencing results, and the expression level of these genes was further verified by immunohistochemistry. In addition, Ki67, VEGF, and p53 of the tumour tissues were also verified by immunohistochemistry.ResultsIn tumour tissues, mRNA sequencing showed that PTBP1 and EIF5A were significantly overexpressed in primary pituitary adenomas and SLC27A1 was significantly overexpressed in aggressive pituitary adenomas. Also in the pituitary adenoma cell line (AtT20), SLC27A1 expression levels were suppressed by TMZ treatment. Subsequent immunohistochemistry confirmed the sequencing results.ConclusionHigh expression of SLC27A1 and low expression of EIF5A and PTBP1 may be potential indicators to predict the progression of aggressive pituitary adenomas, and patients with high SLC27A1 subtype may be sensitive to TMZ in clinical treatments. |
| first_indexed | 2024-12-12T07:41:44Z |
| format | Article |
| id | doaj.art-de92c297e79b4619991f561131809540 |
| institution | Directory Open Access Journal |
| issn | 2296-875X |
| language | English |
| last_indexed | 2024-12-12T07:41:44Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Surgery |
| spelling | doaj.art-de92c297e79b4619991f5611318095402022-12-22T00:32:46ZengFrontiers Media S.A.Frontiers in Surgery2296-875X2022-06-01910.3389/fsurg.2022.923143923143Identification and Verification of SLC27A1, PTBP1 and EIF5A With Significantly Altered Expression in Aggressive Pituitary AdenomasJianhua Cheng0Ruya Sun1Ding Nie2Bin Li3Song Bai Gui4Chu Zhong Li5Ya Zhuo Zhang6Peng Zhao7Department of Cell and Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaDepartment of Biomedical Informatics, Department of Physiology and Pathophysiology, Center for Noncoding RNA Medicine, MOE Key Lab of Cardiovascular Sciences, School of Basic Medical Sciences, Peking University, Beijing, ChinaDepartment of Cell and Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaDepartment of Cell and Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaNeurosurgical Department, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaDepartment of Cell and Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaDepartment of Cell and Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, ChinaNeurosurgical Department, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaBackgroundAggressive pituitary adenoma encircling the internal carotid artery has a poor clinical prognosis because of a high surgical risk and a high recurrence rate. This seriously affects patients’ quality of life and yet there is no effective medical treatment. The European Diagnostic Guidelines have recommended the use of temozolomide (TMZ) for these aggressive pituitary adenomas, but the treatment remission rate has been less than 50%.MethodsIn this study, transcriptome sequencing of pituitary tumour tissues and TMZ-treated pituitary tumour cell lines were employed to explore the significance gene expressions affecting the efficacy of TMZ treatment for pituitary tumours. To clarify the roles of these gene expressions, six adult patients with pituitary adenomas treated in Tiantan Hospital from 2015 to 2020 and a pituitary adenoma cell line (Att20 sensitive to TMZ treatment) were analyzed by mRNA transcriptome sequencing. The differentially expressed genes were assayed by analyzing the sequencing results, and the expression level of these genes was further verified by immunohistochemistry. In addition, Ki67, VEGF, and p53 of the tumour tissues were also verified by immunohistochemistry.ResultsIn tumour tissues, mRNA sequencing showed that PTBP1 and EIF5A were significantly overexpressed in primary pituitary adenomas and SLC27A1 was significantly overexpressed in aggressive pituitary adenomas. Also in the pituitary adenoma cell line (AtT20), SLC27A1 expression levels were suppressed by TMZ treatment. Subsequent immunohistochemistry confirmed the sequencing results.ConclusionHigh expression of SLC27A1 and low expression of EIF5A and PTBP1 may be potential indicators to predict the progression of aggressive pituitary adenomas, and patients with high SLC27A1 subtype may be sensitive to TMZ in clinical treatments.https://www.frontiersin.org/articles/10.3389/fsurg.2022.923143/fullaggressive pituitary adenomTMZSLC27A1PTBP1recurrent pituitary adenomaprimary pituitary adenoma |
| spellingShingle | Jianhua Cheng Ruya Sun Ding Nie Bin Li Song Bai Gui Chu Zhong Li Ya Zhuo Zhang Peng Zhao Identification and Verification of SLC27A1, PTBP1 and EIF5A With Significantly Altered Expression in Aggressive Pituitary Adenomas Frontiers in Surgery aggressive pituitary adenom TMZ SLC27A1 PTBP1 recurrent pituitary adenoma primary pituitary adenoma |
| title | Identification and Verification of SLC27A1, PTBP1 and EIF5A With Significantly Altered Expression in Aggressive Pituitary Adenomas |
| title_full | Identification and Verification of SLC27A1, PTBP1 and EIF5A With Significantly Altered Expression in Aggressive Pituitary Adenomas |
| title_fullStr | Identification and Verification of SLC27A1, PTBP1 and EIF5A With Significantly Altered Expression in Aggressive Pituitary Adenomas |
| title_full_unstemmed | Identification and Verification of SLC27A1, PTBP1 and EIF5A With Significantly Altered Expression in Aggressive Pituitary Adenomas |
| title_short | Identification and Verification of SLC27A1, PTBP1 and EIF5A With Significantly Altered Expression in Aggressive Pituitary Adenomas |
| title_sort | identification and verification of slc27a1 ptbp1 and eif5a with significantly altered expression in aggressive pituitary adenomas |
| topic | aggressive pituitary adenom TMZ SLC27A1 PTBP1 recurrent pituitary adenoma primary pituitary adenoma |
| url | https://www.frontiersin.org/articles/10.3389/fsurg.2022.923143/full |
| work_keys_str_mv | AT jianhuacheng identificationandverificationofslc27a1ptbp1andeif5awithsignificantlyalteredexpressioninaggressivepituitaryadenomas AT ruyasun identificationandverificationofslc27a1ptbp1andeif5awithsignificantlyalteredexpressioninaggressivepituitaryadenomas AT dingnie identificationandverificationofslc27a1ptbp1andeif5awithsignificantlyalteredexpressioninaggressivepituitaryadenomas AT binli identificationandverificationofslc27a1ptbp1andeif5awithsignificantlyalteredexpressioninaggressivepituitaryadenomas AT songbaigui identificationandverificationofslc27a1ptbp1andeif5awithsignificantlyalteredexpressioninaggressivepituitaryadenomas AT chuzhongli identificationandverificationofslc27a1ptbp1andeif5awithsignificantlyalteredexpressioninaggressivepituitaryadenomas AT yazhuozhang identificationandverificationofslc27a1ptbp1andeif5awithsignificantlyalteredexpressioninaggressivepituitaryadenomas AT pengzhao identificationandverificationofslc27a1ptbp1andeif5awithsignificantlyalteredexpressioninaggressivepituitaryadenomas |